Share Information
Deltex Medical Group plc (“Deltex Medical” or the “Group”)
Investor Information – matched bargain facility
The following information is intended to act as a summary / guide as to how to trade Deltex Medical ordinary shares on the JP Jenkins’ share matching platform. For definitive information please contact JP Jenkins by telephone on: +44 (0) 20 7469 0937; or via email at info@jpjenkins.com.
Following cancellation of admission of the Group’s ordinary shares (“Shares”) to trading on AIM on 21 February, 2025, the Shares have been admitted onto the JP Jenkins share matching platform under the ticker: DEMG.
Investors wishing to trade in the Shares can do so through their stockbroker.
Trades will be conducted where JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK-regulated stockbroker.
The indicative pricing for the Shares – as well as the transaction history – is available on the JP Jenkins’ website at www.jpjenkins.com.
Please note that: (i) there will be fees payable to JP Jenkins when trading the Shares; and (ii) purchases of Shares are likely to incur Stamp duty Reserve tax (SDRT). For more information, please call JP Jenkins on +44 (0) 20 7469 0937 or by emailing them at: info@jpjenkins.com
Number of shares in issue
The Company’s issued share capital comprises 1,896,025,700 ordinary shares of 0.01p each. All of the shares are fully paid; no shares are held as treasury shares. The percentage of shares not held in public hands is 20.46%.
Significant shareholders
- Nigel Keen – 18.70%
- Janus Henderson Investors – 8.25%
- Mr Michael Stubbs – 6.64%
- Herald Investment Management Limited – 5.68%
- Mr John T Reilly – 5.59%
- Llewellyn Family – 4.84%
- Mr Mark Bradshaw – 4.46%
- Mr Alasdair Locke – 4.38%
This information was last updated on 16 January 2025.
